Experience of introducing the UroLift System to the Urological Investigations Unit This article is sponsored by Teleflex

Article Sidebar

PDF
Published: Feb 26, 2024
Keywords:
teleflex, urolift, urology, surgery, daycase

Main Article Content

Mr. Nicholas Bryan, Consultant Urologist
Urology Diagnostic Unit (UDU), Calderdale and Huddersfield NHS Foundation Trust

Abstract

This article is sponsored by Teleflex

Downloads

Download data is not yet available.

Article Details

How to Cite
Bryan, N. (2024). Experience of introducing the UroLift System to the Urological Investigations Unit: This article is sponsored by Teleflex. The Journal of One-Day Surgery, 34(1). Retrieved from https://jods.online/index.php/jods/article/view/97
Issue
Vol. 34 No. 1 (2024): JODS February 2024
Section
Strategic Alliance Partners
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

CC Attribution-NonCommercial-NoDerivatives 4.0

Additional License Terms

Author Biography

Mr. Nicholas Bryan, Consultant Urologist, Urology Diagnostic Unit (UDU), Calderdale and Huddersfield NHS Foundation Trust

This article is sponsored by Teleflex

References

Berry, S.J., et al., The Development of Human Benign Prostatic Hyperplasia with Age, J Urology 1984; 132: 474-479.

GIRFT. Clinically-led Specialty Outpatient Guidance. Practical OPD guidance for 17 services to maximise efficiency and reduce waiting times for patients. NHS England. April 2023.

GIRFT. Urology National Specialty Report. 2018.

NICE. (2021). Urolift for treating lower urinary tract symptoms of benign prostatic hyperplasia. Medical Technologies Guidance [MTG58]. May 2021.

GIRFT, CPOC, and BADS (2020). Report: National Day Surgery Delivery Pack. September 2021.

NICE Shared Learning Case Study. Treating Benign Prostatic Obstruction (BPO) with UroLift in an outpatient setting. NHS Fife. June 2020.

Roehrborn, C.G. et al. (2013). Multi-Center randomized controlled blinded study of the prostatic urethral lift for the treatment of LUTS associated with prostate enlargement due to BPH: the L.I.F.T. study. J Urol, 190(6), pp. 2161-2167.

Shore, N. et al. (2014) Prospective multi-center study elucidating patient experience after prostatic urethral lift. Can J Urol, 21(1), pp. 7094-7101.

Roehrborn, C. et al. (2017). Five year results of the prospective randomized controlled prostatic urethral LIFT study. Can J Urol, 24(3), pp. 8802–8813.

Rochester, M. et al. (2023). Prostatic urethral lift for subjects in urinary retention (PULSAR): 12-Month results of a prospective controlled trial compared with real-world outcomes. BJUI Compass. https://doi.org/10.1002/bco2.280.

European Association of Urology. (2023). EAU Guidelines on Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO).

NICE Resource Impact Template: Benign prostatic technologies – Greenlight (MTG29), Rezum (MTG49), UroLift (MTG58), Plasma system (MTG53) and mTURP. March 2022.